Antimicrobial fusion compounds and uses thereof

a technology of fusion compounds and antimicrobials, applied in the field of antimicrobial fusion compounds, can solve the problems of drug loss, high morbidity around the world, and growing problem of microbial resistance to such agents, and achieve the effect of optimal effectiveness

Inactive Publication Date: 2016-03-10
VALIANT BIOPHARMA
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides a fusion protein that can be used to treat and prevent microbial infections. This protein comprises a Type 1 Ribosome Inactivating Protein and a polypeptide capable of viral entry inhibition or a Cationic AntiMicrobial Peptide. The fusion protein can be administered orally and is effective against a broad range of microbial infections, including viral infections. This patent is useful for developing pharmaceutical compositions and methods of treating microbial infections in humans and animals.

Problems solved by technology

Microbial infections affect human beings and animals and cause a high level of morbidity around the world.
However, some antimicrobial agents are associated with undesirable side effects and the problem of microbial resistance to such agents is a growing problem.
Accordingly, once a virus acquires resistance to the mono-functional antiviral drug, the drug loses its effectiveness.
Also, at present no therapeutics are available for a number of animal viruses including for example White Spot Syndrome Virus (WSSV), Porcine Epidemic Diarrhoea Virus (PEDV), Porcine Reproductive & Respiratory Syndrome Virus (PRRSV) and the like.
Effective vaccines for these viruses and most other viruses are difficult to develop due to their high mutation rate.
Also, vaccines that work for one geographical strain often do not work well for other geographical strains of the same virus.
Enfuvirtide is a modified protein which is produced by synthesis and is known to be an expensive mode of treatment which is reported to be in the region of USD25,000 per year per person.
Its mode of administration is also very inconvenient as it is introduced into the body by subcutaneous injection twice daily.
In fact, ROCHE has made several press releases before that production volume of antiviral drugs TAMIFLU® and RELENZA® may be seriously limited by the supply of shikimic acid.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antimicrobial fusion compounds and uses thereof
  • Antimicrobial fusion compounds and uses thereof
  • Antimicrobial fusion compounds and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0139]Construction and Design of Expression Vector

[0140]The gene encoding RetroMAD1 A-B-C with SEQ ID NO:1 was synthesized and cloned into backbone of vector pGA4 at the KpnI / SacI site by contract service (GeneArt AG, Germany). The expected product size was 1140 bp, which encoded a 379 amino acid and an expected size of 41.2 kDa. The polynucleotide sequence and the translated polypeptide sequence are shown in FIG. 1. The gene was sub-cloned into a pET expression vector (Novagen), pET-26(b) at the NcoI / HindIII sites. Kanamycin was used as a marker for selection and maintenance of culture purposes. This vector was inducible under the addition of isopropyl-beta-D-thiogalactopyranoside (IPTG). The plasmid, pRMD1 was then transformed into BL21(DE23) cells (Novagen) and plated on a selective media with Kanamycin.

[0141]Expression of RetroMAD1 from E. coli

[0142]One recombinant clone was grown in 10 ml of LB Bertani (DIFCO) medium, supplemented with 30 μg / ml kanamycin, at 37° C. overnight. ...

example 2

[0149]Virus Stocks

[0150]The herpes simplex virus type-1 (HSV-1) and type-2 (HSV-2) were obtained from Medical Microbiology Department in the Faculty of Medicine, University of Malaya. The virus stock was prepared by inoculating monolayer of vero cells in a 25-cm2 tissue culture flask with virus diluted 1:5 to 1:10 in 1 mL of Dulbecco's Modified Eagle Medium (DMEM) (HyClone) containing 2% Fetal bovine serum (FBS) (HyClone). The flask was placed in an incubator at 37° C. to allow virus adsorption. After 1 hour, 4 mL of DMEM supplemented with 2% FBS was added and the cells were allowed to continue propagating at 37° C. for 6 to 7 days until the cytophatic effect (CPE) are confirmed. Cell debris was removed by centrifugation at 1,500×g for 5 minutes. The viral supernatant was collected in aliquots of 1 mL each and stored at −80° C. until further use.

[0151]Virus Titration by Plaque Assay

[0152]The virulence expressed as plaque forming unit per millilitre (PFU / ml), of each HSV type was tit...

example 3

[0160]Virus Stocks

[0161]The dengue virus type-1 (DENY-1), type-2 (DENV2), type-3 (DENV-3) and type-4 (DENV-4) strain used in this study is a prototype of Hawaii, New Guinea C, H87 and H241 strain respectively (courtesy of Medical Microbiology Department in the Faculty of Medicine, University of Malaya). The virus stock was prepared by inoculating monolayer of C6 / 36 cells in a 25-cm2 tissue culture flask with virus diluted 1:5 to 1:10 in 1 mL of Leibovitz's L-15 containing 2% FBS. The flask was placed in an incubator at 28° C. to allow virus adsorption. After 1 hour, 4 mL of Leibovitz's L-15 supplemented with 2% FBS was added and the cells were allowed to continue propagating at 28° C. for 6 to 7 days until the cytophatic effect (CPE) are confirmed. Cell debris was removed by centrifugation at 1,500×g for 5 minutes. The viral supernatant was collected in aliquots of 1 mL each and stored at −80° C. until further use.

[0162]Virus Titration by Plaque Assay

[0163]The virulence expressed as...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A fusion protein comprising at least one Type 1 Ribosome Inactivating Protein, polypeptide B; and at least one polypeptide A capable of viral entry inhibition; and / or at least one Cationic AntiMicrobial Peptide, polypeptide C.

Description

FIELD OF THE INVENTION[0001]The present invention relates to antimicrobial fusion compounds, in particular polypeptides, and fragments thereof and to their use as therapeutic agents in microbial infections.BACKGROUND TO THE INVENTION[0002]Microbial infections affect human beings and animals and cause a high level of morbidity around the world. Microbial infectious agents include protozoan parasites, bacteria and fungi for which antimicrobial agents are often available. However, some antimicrobial agents are associated with undesirable side effects and the problem of microbial resistance to such agents is a growing problem.[0003]Microbial infectious agents also include viruses which are the cause of many widespread infectious diseases afflicting mankind as well as mankind's companion animals and also animals farmed specifically for human food. Most of the presently available antiviral drugs used in human therapeutic applications are mono-functional in nature and block only one specif...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): C12N9/24C07K14/47
CPCC12N9/2497C07K14/4723A61K38/00C12Y302/02022C07K2319/00A61K38/1709C07K19/00C12N15/62
Inventor ABU BAKAR, AG., MUHAMMAD SAGAFUNG, ENG HUAN
Owner VALIANT BIOPHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap